Guideline

. 2018 Dec 14;24(46):5189-5202.

doi: 10.3748/wjg.v24.i46.5189.

Chinese consensus on management of tyrosine kinase inhibitor-associated side effects in gastrointestinal stromal tumors

Jian Li¹, Ming Wang², Bo Zhang³, Xin Wu⁴, Tian-Long Lin², Xiu-Feng Liu⁵, Ye Zhou⁶, Xin-Hua Zhang⁷, Hao Xu⁸, Li-Jing Shen⁹, Jing Zou¹⁰, Ping Lu¹¹, Dong Zhang¹², Wei-Jun Gu¹³, Mei-Xia Zhang¹⁴, Jian Pan¹⁵, Hui Cao¹⁶; Chinese Society of Surgeons for Gastrointestinal Stromal Tumor of the Chinese Medical Doctor Association

Affiliations

¹ Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital and Institute, Beijing 100142, China.
² Department of Gastrointestinal Surgery, Reiji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200127, China.
³ Department of Gastrointestinal Surgery, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China.
⁴ Department of General Surgery, the General Hospital of the People's Liberation Army, Beijing 100853, China.
⁵ Department of Oncology, The Chinese People's Liberation Army 81 Hospital, Nanjing 210031, Jiangsu Province, China.
⁶ Department of Gastric Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
⁷ Department of Gastrointestinal Surgery, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, Guangdong Province, China.
⁸ Department of General Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing 320100, Jiangsu Province, China.
⁹ Department of Hematology, Ren Ji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai 200240, China.
¹⁰ Department of Respirology, Ren Ji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai 200240, China.
¹¹ Department of Dermatology, Ren Ji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai 200240, China.
¹² Department of Nephrology, The General Hospital of the People's Liberation Army, Beijing 100853, China.
¹³ Department of Endocrinology, The General Hospital of the People's Liberation Army, Beijing 100853, China.
¹⁴ Department of Ophthalmology, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China.
¹⁵ Department of Oral and Maxillofacial Surgery, West China Hospital of Stomatology, Sichuan University, Chengdu 610041, Sichuan Province, China.
¹⁶ Department of Gastrointestinal Surgery, Reiji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200127, China. caohuishcn@hotmail.com.

PMID: 30581268
PMCID: PMC6295840
DOI: 10.3748/wjg.v24.i46.5189

Guideline

Chinese consensus on management of tyrosine kinase inhibitor-associated side effects in gastrointestinal stromal tumors

Jian Li et al. World J Gastroenterol. 2018.

. 2018 Dec 14;24(46):5189-5202.

doi: 10.3748/wjg.v24.i46.5189.

Authors

Affiliations

¹ Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital and Institute, Beijing 100142, China.
² Department of Gastrointestinal Surgery, Reiji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200127, China.
³ Department of Gastrointestinal Surgery, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China.
⁴ Department of General Surgery, the General Hospital of the People's Liberation Army, Beijing 100853, China.
⁵ Department of Oncology, The Chinese People's Liberation Army 81 Hospital, Nanjing 210031, Jiangsu Province, China.
⁶ Department of Gastric Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
⁷ Department of Gastrointestinal Surgery, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, Guangdong Province, China.
⁸ Department of General Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing 320100, Jiangsu Province, China.
⁹ Department of Hematology, Ren Ji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai 200240, China.
¹⁰ Department of Respirology, Ren Ji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai 200240, China.
¹¹ Department of Dermatology, Ren Ji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai 200240, China.
¹² Department of Nephrology, The General Hospital of the People's Liberation Army, Beijing 100853, China.
¹³ Department of Endocrinology, The General Hospital of the People's Liberation Army, Beijing 100853, China.
¹⁴ Department of Ophthalmology, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China.
¹⁵ Department of Oral and Maxillofacial Surgery, West China Hospital of Stomatology, Sichuan University, Chengdu 610041, Sichuan Province, China.
¹⁶ Department of Gastrointestinal Surgery, Reiji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200127, China. caohuishcn@hotmail.com.

PMID: 30581268
PMCID: PMC6295840
DOI: 10.3748/wjg.v24.i46.5189

Abstract

Tyrosine kinase inhibitors (TKIs) have improved the overall survival of patients with gastrointestinal stromal tumors (GISTs), but their side effects can impact dose intensity and, consequently, the clinical benefit. To date, no guideline or consensus has been published on the TKI-associated adverse reactions. Therefore, the Chinese Society of Surgeons for Gastrointestinal Stromal Tumor of the Chinese Medical Doctor Association organized an expert panel discussion involving representatives from gastrointestinal surgery, medical oncology, cardiology, dermatology, nephrology, endocrinology, and ophthalmology to consider the systemic clinical symptoms, molecular and cellular mechanisms, and treatment recommendations of GISTs. Here, we present the resultant evidence- and experience-based consensus to guide the management of TKI-associated side events in clinical practice.

Keywords: China; Consensus guideline; Gastrointestinal stromal tumor; Side effects; Tyrosine kinase inhibitors.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest statement: All the authors report no conflicts of interest in this work.

Cited by

The management of imatinib-associated severe skin rash in gastrointestinal stromal tumor: desensitization therapy and pharmacogenetic investigation.
Liu X, Pi M, Chen M, Cai S, He Y, Tang KJ, Zhang X, Xia Y. Liu X, et al. Oncologist. 2025 Jul 4;30(7):oyaf176. doi: 10.1093/oncolo/oyaf176. Oncologist. 2025. PMID: 40592735 Free PMC article.
Individualized Management of Blood Concentration in Patients with Gastrointestinal Stromal Tumors.
Xu H, Liu Q. Xu H, et al. Onco Targets Ther. 2021 Jan 5;13:13345-13355. doi: 10.2147/OTT.S279998. eCollection 2020. Onco Targets Ther. 2021. PMID: 33456310 Free PMC article. Review.
Imatinib-associated skin rash is related to treatment outcome in patients with unresectable and/or metastatic gastrointestinal stromal tumor.
Zhang M, Li L, Sun H, Tang T, Li Q, Chen L, Chen W. Zhang M, et al. J Gastrointest Oncol. 2022 Feb;13(1):117-125. doi: 10.21037/jgo-22-65. J Gastrointest Oncol. 2022. PMID: 35284105 Free PMC article.
Preoperative imatinib treatment in patients with locally advanced and metastatic/recurrent gastrointestinal stromal tumors: A single-center analysis.
Wang J, Yin Y, Shen C, Yin X, Cai Z, Pu L, Fu W, Wang Y, Zhang B. Wang J, et al. Medicine (Baltimore). 2020 Feb;99(9):e19275. doi: 10.1097/MD.0000000000019275. Medicine (Baltimore). 2020. PMID: 32118738 Free PMC article.
Second-line sunitinib for Chinese patients with advanced gastrointestinal stromal tumor: 37.5 mg schedule outperformed 50 mg schedule in adherence and prognosis.
Zhang C, Zhang C, Zhang T, Liu H, Zhong J, Wang Z, Wang L, Hong L. Zhang C, et al. Transl Cancer Res. 2021 Jul;10(7):3206-3217. doi: 10.21037/tcr-21-613. Transl Cancer Res. 2021. PMID: 35116627 Free PMC article.

See all "Cited by" articles

References

1. Balshem H, Helfand M, Schünemann HJ, Oxman AD, Kunz R, Brozek J, Vist GE, Falck-Ytter Y, Meerpohl J, Norris S, et al. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol. 2011;64:401–406. - PubMed
1. Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002;347:472–480. - PubMed
1. Sutent® Summary of Product Characteristics 2008. Sandwich, Kent, UK: Pfizer Ltd
1. Deininger MW, O’Brien SG, Ford JM, Druker BJ. Practical management of patients with chronic myeloid leukemia receiving imatinib. J Clin Oncol. 2003;21:1637–1647. - PubMed
1. Joensuu H, Trent JC, Reichardt P. Practical management of tyrosine kinase inhibitor-associated side effects in GIST. Cancer Treat Rev. 2011;37:75–88. - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
Other Literature Sources
- The Lens - Patent Citations Database
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Chinese consensus on management of tyrosine kinase inhibitor-associated side effects in gastrointestinal stromal tumors

Affiliations

Chinese consensus on management of tyrosine kinase inhibitor-associated side effects in gastrointestinal stromal tumors

Authors

Affiliations

Abstract

Conflict of interest statement

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Abstract

Conflict of interest statement

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Related information

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical